2231 GMT - PeopleIN's bull at Ord Minnett says industry conditions point to a more stable 2H backdrop for the business, following the sale of the company's health brands. Ord Minnett forecasts 18% Ebitda growth in 2H. "With the business mix skewing to food and infrastructure sectors facing critical staff shortages, we see upside risk to organic growth over the coming 2 years," analyst Ian Munro says. Ord Minnett retains a buy call on PeopleIN, underpinned by what it considers to be attractive earnings multiples and an improving balance sheet. Its price target rises to A$1.03, from A$1.02. PeopleIN ended last week at A$0.71. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 21, 2026 18:31 ET (22:31 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.